

DT02 Rec'd PCT/PTO 3 1 JAN 2005 #5
PCT

PATENT
Attorney Docket No.: 06056-0309US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Patent application of KAMEL KHALILI	: Group Art Unit: : Not Yet Known :
Serial No.:	10/517,710	: Examiner: : Not Yet Assigned :
Filed:	December 10, 2004	: Confirmation No.: : Not Yet Known
For:	METHOD OF CELL GROWTH INHIBITION WITH AGNOPROTEIN	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, submitted herewith are copies of the references listed in the accompanying Form PTO-1449, except for any US patents and published US patent applications which may be listed.

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8(a)	
I hereby certify that this paper, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date indicated below, with sufficient postage, as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
BY	<u><i>Debra M. Collins</i></u>
DATE:	<u><i>January 28, 2005</i></u>


The Examiner is respectfully requested to review the items listed on the attached form and make them of record in the instant application as required by M.P.E.P. §609. It is requested that the Examiner initial the enclosed duplicate Form 1449, and return one copy to the undersigned.

This Statement should not be construed as a representation that the cited references are material or that more relevant prior art does not exist.


This Statement is being submitted before receipt of any office action on the merits. Thus, no fee is due for the filing of this paper. However, if a fee is due, please charge deposit account 50-0573.

Respectfully submitted,

KAMEL KHALILI



DANIEL A. MONACO
Registration No. 30,480
DRINKER BIDDLE & REATH LLP
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
(215) 988-3312 - Phone
(215) 988-2757 - Fax
Attorney for the Applicant

SUBSTITUTE FORM PTO-1449 DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 06056-0309051	SERIAL NO. 10/517,710
INFORMATION DISCLOSURE STATEMENT 		APPLICANT: KAMEL KHALILI	
		FILING DATE December 10, 2004	GROUP Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	AA	US 5,643,567	07/01/1997	Hung et al.	424	93.2	
	AB	US 5,801,029	09/01/1998	McCormick	435	172.3	
	AC	US 5,814,315	09/29/1998	Hung et al.	424	93.2	
	AD	US 6,197,754	03/06/2001	Hung et al.	514	44	
	AE	US 2001/0006633	07/05/2001	Kim	424	93.6	
	AF	US 6,296,845	10/02/2001	Sampson-Johannes et al.	424	93.2	
	AG	US 2001/0048920	12/06/2001	Lee et al.	424	93.21	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AH	Richard J. Frisque et al., "Human Polyomavirus JC Virus Genome", <i>Journal of Virology</i> , Vol. 51, No. 2, pp. 458-469 (1984).
	AI	DeValle L et al. (Feb. 11, 2002), "Expression of Human Neurotropic Polyomavirus JCV Late Gene Product Agnoprotein in Human Medullablastoma," <i>J. Nat. Cancer Inst.</i> 94(4).
	AJ	Cubitt CL et al. (2001), "Predicted Amino Acid Sequences for 100 JCV Strains," <i>J Neurovirol.</i> , 7(4): 339-344.
	AK	Jobes DV et al. (1999), "A Novel JC Virus Variant Found in the Highlands of Papua New Guinea Has a 21-Base Pair Deletion in the Agnoprotein Gene," <i>J. Hum. Virol.</i> 2(6): 350-358.
	AL	Safak M et al. (2001), "Interaction of JC Virus Agno Protein with T Antigen Modulates Transcription and Replication of the Viral Genome in Glial Cells," <i>J. Virol.</i> 75(3): 1476-1486.
	AM	Stacy T et al. (1989), "Simian Virus 40 Host Range/Helper Function Mutations Cause Multiple Defects in Viral Late Gene Expression," <i>J. Virol.</i> 63(12): 5208-5215.
	AN	Khalili K et al. (1988), "Carboxyl-terminal mutants of the large tumor antigen of simian virus 40: A role for the early protein late in the lytic cycle," <i>Proc. Natl. Acad. Sci. USA</i> 85: 354-358.
	AO	Resnick J and Shenk T (1986), "Simian Virus 40 Agnoprotein Facilitates Normal Nuclear Location of the Major Capsid Polypeptide and Cell-to-Cell Spread of Virus," <i>J. Virol.</i> 60(3): 1098-1106.
	AP	Carswell S and Alwine J, "Simian Virus 40 Agnoprotein Facilitates Perinuclear-Nuclear Localization of VP1, the Major Capsid Protein," <i>J. Virol.</i> 60(3): 1055-1061.
	AQ	Hay N and Aloni Y (1985), "Attenuation of Late Simian Virus 40 mRNA Synthesis Is Enhanced by the Agnoprotein and Is Temporally Regulated in Isolated Nuclear Systems," <i>Mol. and Cell. Biol.</i> 5(6): 1327-1334.
	AR	Nomura S et al (1983), "Subcellular Localization of the Simian Virus 40 Agnoprotein," <i>J. Virol.</i> 45(1): 428-433.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ATTY. DOCKET NO.
06056-0309US1SERIAL NO.
10/517,710

INFORMATION DISCLOSURE STATEMENT

APPLICANT:
KAMEL KHALILIFILING DATE
December 10, 2004GROUP
Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AS	Alwine JC (1982), "Evidence for Simian Virus 40 Late Transcriptional Control: Mixed Infections of Wild-Type Simian Virus 40 and a Late Leader Deletion Mutant Exhibit <i>trans</i> Effects on Late Viral RNA Synthesis," <i>J. Virol.</i> 42(3): 798-803.
	AT	Hay N et al. (1982), "Attenuation in the Control of SV40 Gene Expression," <i>Cell.</i> 29: 183-193.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.